Jacob Sands on DeLLphi-305 and First-Line Maintenance in Extensive-Stage SCLC
At ESMO 2026, Jacob Sands reviews DeLLphi-305, a phase 3 trial comparing tarlatamab plus durvalumab with durvalumab alone as maintenance after first-line induction in extensive-stage small cell lung cancer. He discusses survival, the durability of disease control, adverse events, and access to treatment.
0
0